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Abstract
IMPORTANCE—Obesity affects nearly one sixth of U.S. children and results in alterations to 
body composition and physiology that can affect drug disposition, possibly leading to therapeutic 
failure or toxicity. The depth of available literature regarding obesity’s effect on drug safety, 
pharmacokinetics (PK) and dosing in obese children is unknown.
OBJECTIVE—To perform a systematic literature review describing the current evidence of the 
effect of obesity on drug disposition in children.
EVIDENCE REVIEW—We searched the Medline, Cochrane, and Embase databases (January 
1970–December 2012) and included studies if they contained clearance, volume of distribution, or 
drug concentration data in obese children (age ≤18 years). We compared exposure and weight-
normalized volume of distribution and clearance between obese and non-obese children. We 
Address correspondence to: Daniel K. Benjamin Jr., MD, PhD, MPH, Duke Clinical Research Institute, 2400 Pratt Street, Durham, 
NC 27705; phone: 919-668-7081; danny.benjamin@duke.edu..
*See Appendix for listing of committee members
Conflict of interest: The authors have no conflicts of interest to disclose.
Author Contributions: Drs Harskamp-van Ginkel and Watt had full access to all the data in the study and take responsibility for the 
integrity of the data and the accuracy of the data analysis. Study concept and design: Harskamp-van Ginkel, Becker, Cohen-
Wolkowiez, Barrett, Benjamin, Siegel, Banks, Watt
Analysis and interpretation of data: Harskamp-van Ginkel, Hill, Becker, Testoni, Gonzalez, Benjamin, Siegel, Watt
Drafting of the manuscript: Harskamp-van Ginkel, Becker
Critical revision of the manuscript for important intellectual content: Hill, Testoni, Cohen-Wolkowiez, Gonzalez, Barrett, Benjamin, 
Siegel, Banks, Watt
Study supervision: Watt, Barrett, Siegel
Additional Contribution: The authors would like to thank Florence Chang of the National Library of Medicine, National Institutes of 
Health, for advice and guidance with the literature search.
HHS Public Access
Author manuscript
JAMA Pediatr. Author manuscript; available in PMC 2016 July 01.
Published in final edited form as:













explored the relationship between drug physicochemical properties and clearance and volume of 
distribution.
FINDINGS—Twenty studies met inclusion criteria and contained pharmacokinetic data for 21 
drugs. The median number of obese children studied per drug was 10 (range 1–112), ages ranged 
from 0–29 years. Dosing schema varied and were based on a fixed dose (n=6, 29%), body weight 
(n=10, 48%), and body surface area (n=4, 19%). Clinically significant pharmacokinetic alterations 
were observed in obese children for 65% (11/17) of studied drugs. Pharmacokinetic alterations 
resulted in substantial differences in exposure between obese and non-obese children for 38% 
(5/13) of drugs. We found no association between drug lipophilicity or Biopharmaceutical Drug 
Disposition Classification System class and changes in volume of distribution or clearance due to 
obesity.
CONCLUSIONS AND RELEVANCE—Consensus is lacking on the most appropriate weight-
based dosing strategy. Prospective pharmacokinetic trials in obese children are needed to ensure 
therapeutic efficacy and enhance drug safety.
The prevalence of childhood obesity has stabilized at epidemic proportions. Nearly 1 out of 
every 6 children or adolescents living in the U.S. has a body mass index (BMI) for age and 
sex above the 95th percentile and is considered obese.1 Obese children experience increased 
rates and severity of multiple disease states, require more frequent and more complex 
medical interventions,2–7 and use significantly more prescription medications than their non-
obese peers.8
Relatively little is known about the impact of childhood obesity on drug pharmacokinetics 
(PK). Obesity demonstrates important alterations in physiology such as changes in tissue 
composition, increased circulating blood volume and cardiac output, altered regional flow 
distribution, and impaired liver and kidney function.9–11 All of these physiologic alterations 
can affect PK parameters including drug absorption, volume of distribution (V), metabolism, 
and elimination.12–14 Furthermore, physiochemical properties of a drug, such as lipid 
solubility or relative protein binding, might have differential effects on drug PK in obese 
versus non-obese children.14 To account for these physiologic and pharmacologic factors, 
some clinicians adjust weight-based dosing using various metrics of body size, such as ideal 
body weight (IBW). However, these dosing strategies are largely based on theoretical 
considerations or extrapolated from studies in adults.15 Currently, there is no 
comprehensive, evidence-based understanding of the impact of childhood obesity on drug 
PK.
To better understand the current evidence base, we performed a systematic review of 
published PK studies conducted over the preceding 4 decades in obese children and 
adolescents. We addressed the question of whether critical obesity-related physiologic 
parameters change drug PK in children and evaluated the impact on PK of important drug 
physiochemical properties including lipophilicity (logP) and Biopharmaceutical Drug 
Disposition Classification System (BDDCS) class, a classification based on drug 
permeability and solubility.16
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We performed a systematic literature review using the Medline, Cochrane, and Embase 
databases (January 1970–December 2012). The search strategy was defined in collaboration 
with librarians at Duke University Medical Center Library and the National Library of 
Medicine. Search terms included: pharmacokinetics, pharmacodynamics, PK/PD, 
medication, dosing, dose, dosage, overweight, obesity, and obese. Exact search strategies are 
displayed in Supplemental eTables 1 and 2. There were no language restrictions. We 
identified additional studies through pertinent review of article bibliographies and 
conference abstracts.
Study Selection
We compiled the final search results into a single library using Endnote X5 (Thomson 
Reuters, San Francisco, CA). We independently reviewed study abstracts for inclusion in the 
final analysis (M.G. and K.B.). If an abstract lacked sufficient detail, the full article was 
reviewed. We included studies if they contained any PK data for obese children (ages 2–18 
years) including clearance (CL), V, area under the curve, half-life, or drug concentration 
data. Articles with only pharmacodynamics results were not included. Because definitions of 
obesity and overweight have varied over the years, we included all studies in which the 
authors used an accepted definition of obesity, regardless of the criteria used. Studies that 
included both obese and overweight children in the same analysis group were also included 
but are clearly identified.17–23 The different phases of systematic review are displayed in a 
flowchart, as described by the PRISMA 2009 statement24 (Figure 1).
Data Extraction
We extracted dosing and PK data and information regarding the body weight measurement 
used for dosing. Total body measurement (TBM) was defined as the actual total body weight 
or body surface area (BSA) of the child. IBW was defined as the weight at the 50th 
percentile of a weight for height on a sex-adjusted growth curve. Adjusted body 
measurement was defined as any measurement that relied on scaling between ideal and total 
body weight (e.g., IBW + 40%*[total body weight – IBW]) or adjusted BSA. We extracted 
TBM-normalized CL (ml/min/kg) or V (L/kg) values when they were reported or calculated 
TBM-normalized values by dividing CL and V with weights reported in the original source 
(individual or study mean weight values). Whenever possible, data were included for 
children only. We did not extract pharmacodynamics or safety data, as most studies did not 
report these data and were not powered to do so.
Comparison of PK Data in Obese and Non-Obese Control Children
We qualified exposure to the studied drug in obese children as sub-therapeutic, therapeutic, 
or supra-therapeutic based on target ranges provided in the original source (e.g., a target 
trough level or area under the curve). We compared exposure and weight-normalized PK 
parameters in obese children to non-obese controls within each study when available and 
expressed values in obese children as a percentage (%) of controls. To evaluate the 
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association between changes in CL or V and the drug’s physicochemical properties, we 
plotted the ratio of CL in obese children to CL in control children, and the ratio of V in these 
2 populations against the drug’s logP and BDDCS class. V and CL were normalized to 
actual body weight—either total body weight or BSA, depending on the weight metric used 
to dose the respective drug.
RESULTS
We identified 1888 unique publications, of which 1868 (99%) were excluded because they 
did not describe PK of an exogenous drug, they did not contain any PK data, or they did not 
include overweight or obese children (Figure 1). The remaining 20 publications contained 
PK data for 21 drugs, including 7 anti-neoplastic drugs, 4 anticonvulsants, 4 antibiotics, 3 
analgesic/anesthetic drugs, 2 respiratory stimulants, and 1 immunosuppressant (Table 1). Six 
out of 21 (29%) drugs were not studied in a formal prospective PK trial (gentamicin29; 
vancomycin17,18,30; valproic acid19; divalproex sodium20; busulfan21; and cyclosporine36). 
PK data for these studies were collected following drug administration per standard of care, 
frequently with sparse sampling.
Study Population
Study definitions of obesity and overweight varied. The majority of studies used the 
currently accepted Centers for Disease Control and Prevention definition for children of 
BMI percentile ≥95% for obesity and ≥85% for overweight (18/21 drugs). Other definitions 
included IBW percentile ≥125% and ≥115% (2/21), weight-for-height percentile ≥75% 
(1/21), and absolute BMI ≥ 25 (1/21). Thirteen out of 20 (65%) studies described PK 
parameters for obese children separately versus combining obese and overweight children in 
1 analysis group. The median number of obese children studied per drug was 10 (range 1–
112 subjects), with 12/21 (57%) studies including ≤10 obese children. Patient ages ranged 
from 0–29 years (1 study described PK in children and adults together).19
Studied Dosing Schedules and Exposure
Dosing schema showed considerable variability. Drugs were dosed using a fixed dose (n=6, 
29%), based on body weight (n=10, 48%) or BSA (n=4, 19%), or based on body weight in 1 
study and BSA in another study (n=1, 5%). When drugs were dosed by body weight or BSA, 
the body weight measurement used for dosing was as follows: TBM (n=7, 33%), adjusted 
body measurement (n=5, 24%), or both (n=3, 14%). No drug was dosed based on IBW 
(Table 2).
Exposure data in obese children were available for 17 drugs, and a non-obese control 
comparison group was available for 13 of these drugs (Table 2). Compared with controls, 
obese children demonstrated meaningful differences in exposure for 5/13 drugs (38%), 
including 4/5 with increased exposure in the obese patients. Dosing by TBM demonstrated 
sub- or supra-therapeutic exposures for 4/10 drugs, while dosing strategies using various 
adjusted body measurement strategies resulted in appropriate exposures for 8/8 drugs (Table 
2).
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Pharmacokinetic Changes Due to Obesity
PK parameters were compared between obese and non-obese controls for 17 drugs, a 
slightly different set from the drugs with PK data (Table 3). As compared with controls, 
clinically significant PK alterations were seen in obese children for 11/17 (65%) of studied 
drugs, including decreased V (range 65–89% of controls) for 8 drugs, increased V (113%, 
166%) for 2 drugs, decreased CL (range 30–84%) for 5 drugs, and increased CL (222%) for 
1 drug (Table 3).
Figure 2 shows the ratios of V and CL for drugs with different logP and BDDCS class. A 
ratio of 1 indicates that weight-normalized V or CL were identical between obese and non-
obese children, <1 indicates that obese children had a smaller V or CL, and >1 indicates that 
V or CL were higher in obese children. We did not identify any relationship between 
measured logP or BDDCS class and change in V or CL due to obesity.
DISCUSSION
This is the first systematic review of PK studies conducted in obese children. Despite a 
comprehensive review strategy, we identified only 20 studies (evaluating 21 drugs) 
performed over the preceding 4 decades. Many of these studies identified important obesity-
related changes in drug PK. However, the majority included small numbers of children, and 
29% were conducted using therapeutic drug monitoring data and not as part of a formal PK 
trial. Also, many of the drugs that we highlight are not commonly prescribed agents.41,42 
We found no data for several important drug classes for which obesity-related toxic 
overdosing or sub-therapeutic under-dosing have been previously described in adults, 
including acute care, cardiovascular, anesthetic agents, and contraception (including 
emergency contraception).43-50 For contraception, the lack of PK data in obese female 
adolescents is particularly concerning as evidenced by recent studies in obese female adults 
suggesting that higher doses are required to achieve therapeutic exposure and certain 
emergency contraceptive agents are less effective.49,50
Considering the prevalence and tremendous public health impact of childhood obesity, the 
relative paucity of drug PK data is concerning. Kendrick and colleagues completed the only 
prior review of PK studies in obese children (published in 2010), identifying just 10 drugs 
with available PK data. They concluded that clinicians may need to extrapolate from adult 
data while considering the effects of growth and development on PK.51 However, 
subsequent analyses have identified that simple extrapolation from studies in obese adults 
may give false predictions of CL and other PK values.15 These observed differences 
between obese children and adults might be explained by maturational differences in 
expression and activity of enzymatic pathways and/or drug transporters, by differences in 
elimination pathways, or by as yet unexplained differences in drug metabolism.15 
Regardless, important differences exist and highlight the need for conducting PK studies 
specifically in obese children.
In the clinical setting, health care providers sometimes empirically adjust dosing in obese 
children based on perceived differences in PK (e.g., dosing by IBW). In the small number of 
obese children described in this systematic review, the PK differences we identified in obese 
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children (CL was different in 6/15 drugs and V in 10/11 drugs) were not predicted by drug 
logP, and no relationship between BDDCS class and PK changes was observed. Given the 
paucity of systematic data investigating the impact of logP and BDDCS class in obese 
children, these drug characteristics should still be investigated in future studies.12,52 
However, it is also possible that V and CL in obese children are affected by drug-specific 
factors other than logP or BDDCS class. Possible factors include route of absorption, 
metabolic pathway, and route of elimination. A recent study in obese adults reached a 
similar conclusion.14
Given the noted overweight-related alterations in drug exposure and PK, it would seem that 
optimal dosing regimens should be adjusted to account for obesity-related factors. 
Traditionally, a variety of adjustment methods have been proposed, including dosing 
regimens based on IBW, TBM, BSA, various adjusted body measurement formulae, or more 
complex physiologically based formulae, such as the ratio between V and body weight.14 In 
our analysis, there was little consistency in which adjustment methods were used. 
Evaluating exposure levels in obese children by dosing strategy, we found that dosing based 
on TBM resulted in inappropriate exposure for 4/10 drugs. When combined with the 8 drugs 
for which dosing using an adjusted body measurement achieved appropriate exposure, 
approximately two thirds of drugs in this review would result in inappropriate exposure if 
dosed by TBM. However, we cannot predict which drugs should be dosed by total or 
adjusted body measurement and which adjustment method to use to convert from total to 
adjusted body measurement.
The main limitations of our analysis are small study sizes, an overall small number of 
studied drugs, and the heterogeneity in study population and study design for the various PK 
studies that we identified. To maximize the power of this review, notwithstanding 
inconsistent weight categorizations and a small number of available studies, we reviewed all 
studies in obese children. Thirty-five percent included overweight as well as obese children, 
which may have caused underestimation of the effects of obesity. Many of the analyzed PK 
studies used sparse sampling strategies (e.g., therapeutic drug monitoring data) that limit the 
ability to analyze drug PK in a specific age group. For these reasons, we are cautious in 
drawing conclusions and avoid making specific dosing recommendations. Because the data 
are so sparse, we are collaborating with the National Institute of Child Health and Human 
Development in a systematic review of acute care and commonly used drugs to develop a 
PK database in obese children, normal weight children, and obese adults. Data generated 
from this review will be used to make dosing recommendations for obese children when 
possible and identify priority drugs in need of study in this population.
For future PK studies in obese children, we recommend including drugs of different 
therapeutic drug classes. Drug class prioritizing should be based on drug utilization, medical 
need, and expected PK alterations in obesity (based on adult studies).53 Based on our review 
of current PK studies in obese children, we recommend that future PK studies in children: 1) 
describe inclusion criteria, including the definitions of obesity (preferably age- and sex-
adjusted BMI %), age, clinical diagnosis, and co-morbidities; 2) describe demographics of 
both obese and control subjects including age, weight, height, BMI, BMI %, diagnosis, and 
kidney and liver function; 3) provide detailed PK parameters including CL and V estimates 
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by BMI group (>85%, >95%, >97%); and 4) report safety outcomes and, if possible, 
pharmacodynamic outcomes.
In conclusion, this systematic review describes PK changes due to obesity in children. We 
found that an evidence base is broadly lacking. Of the existing data, many of the studies 
were small PK studies or were conducted for drugs that are infrequently prescribed (e.g., 
anti-neoplastic drugs). The studies demonstrated considerable variability in weight-based 
dosing strategies, criteria for obesity, and type of PK analysis. We identified important but 
unpredictable differences in drug CL and V in obese children for two thirds of drugs. 
Furthermore, our analysis demonstrates that dosing based on TBM is often sub-optimal, as 
approximately two thirds of drugs studied demonstrated sub- or supra-therapeutic exposure 
when dosed using TBM. Therefore, given the increasing societal obesity-related morbidity 
and medical expenditure in children, there is an urgent need for formal PK studies in obese 
children to develop evidence-based dosing guidelines. With dedicated PK studies, we can 
determine PK parameters and use them to explore different dosing regimens using modeling 
and simulation. We have provided recommendations for the critical components of these 
future PK studies to standardize design and improve granularity of future structured reviews.
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Figure 2. Relationship Between Obesity-Related Changes in Pk and Drug Physicochemical 
Properties
V and CL ratios plotted by measured logP and BDDCS class. Ratios displayed as obese/
controls. CL and V are weight-normalized (e.g., V in L/kg). If authors did not report weight-
normalized values (antipyrine, carbamazepine, and caffeine), then weight-normalized 
parameters were calculated by dividing reported values by individual or study mean weight 
values. A: V by measured logP; B: V by BDDCS class; C: CL by measured logP; D: CL by 
BDDCS class. V, volume of distribution; Cl, clearance; logP, lipophilicity; BDDCS, 
Biopharmaceutical Drug Disposition Classification System; ace, acetaminophen; ant, 
antipyrine; caf, caffeine; cbz, carbamazepine; dox, doxorubicin; eto, etoposide; gen, 
gentamicin; mer, mercaptopurine; mtx, methotrexate; ten, teniposide; the, theophylline; tob, 
tobramycin; van, vancomycin.
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Table 1
Pharmacokinetic Studies in Obese Children




 Acetaminophen25 12 15 (2) BMI ≥ 95%ile
 Antipyrine26 3 17 (0) BMI ≥ 95%ile
 Propofol27 20 16 (2) BMI ≥ 95%ile
Antibiotics
 Cefazolin28 5 7 (3) BMI ≥ 95%ile
 Gentamicin29 25 10 (4) BMI ≥ 95%ile
 Tobramycin28 5 7 (3) BMI ≥ 95%ile
 Vancomycin17,18,30 112 (0.2, 18) BMI ≥ 85%17,18, ≥ 95%ile30
Anticonvulsants
 Carbamazepine31,19 9 (15, 29) BMI ≥ 95%ile31, BMI ≥ 25
(study mean 30)19
 Divalproex sodium20 5 9 (5, 14) > 115% IBWa
 Midazolam32 - - BMI ≥ 95%ile
 Valproic acid19 5 21 (15, 29) BMI ≥ 25 (study mean 27)
Antineoplastics
 Busulfan21 22 7 (6) BMI ≥ 85%ile
 Cytarabine33 10 9 (2, 18) BMI ≥ 95%ile
 Doxorubicin34,35 4 (9, 16) BMI ≥ 95%ile
 Etoposide33,35 25 9 (2, 18) BMI ≥ 95%ile
 Mercaptopurine22 9 7 (4) 75% W/H
 Methotrexate33 41 9 (2, 18) BMI ≥ 95%ile
 Teniposide33 10 9 (2, 18) BMI ≥ 95%ile
Immunosuppressants
Cyclosporine36 30 + 72 15 (4) BMI ≥ 95% + BMI ≥ 85%ile
Respiratory stimulants
 Caffeine37 3 17 (0) BMI ≥ 95%ile
 Theophylline23 9 - >125% IBW
BMI %, age- and sex-specific BMI percentile (≥85th considered overweight, ≥95th considered obese)38; % IBW, percentile of ideal body weight 
(>120% considered overweight)39; BMI ≥ 25 (considered moderate obesity)40; % W/H, percentile of weight for height.38
a
For divalproex sodium, the authors did not stratify based on obesity, but found an empiric difference in PK for children less than and greater than 
115% IBW.
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Table 2
Drug Exposure in Obese Children by Dosing Method
Drug Dosed per Body weightmeasurement
Exposure in
obesity Obese vs. control
Mercaptopurine22 m2 TBM Subtherapeutic ↓
Vancomycin17,18,30 kg TBM Subtherapeutic17,30 ↔ 17,30
TBM Therapeutic18 ↑ 18
Teniposide33 kg TBM Therapeutic ↔ a
Methotrexate33 m2 TBM Therapeutic ↔ a
Cytarabine33 m2 TBM Therapeutic ↔ a
Theophylline23 kg TBM Not available Not available
Busulfan21 kg TBMb Supratherapeutic ↑ (124%)
Divalproex sodium20 kg TBM Supratherapeutic ↑ (156%)
ABM Therapeutic ↔
Doxorubicin34,35 kg34 TBM Therapeutic Not available
m2 35 ABM Therapeutic Not available
Etoposide33,35 m2 33 TBM Therapeutic ↔ a
m2 35 ABM Therapeutic Not available
Tobramycin28 kg ABM Therapeutic Not available
Cefazolin28 kg ABM Therapeutic Not available
Gentamicin29 kg ABM Therapeutic ↔
Cyclosporine36 kg ABM Therapeutic ↔
Propofol27 kg ABM Therapeutic Not available
Acetaminophen25 Fixed dosec n/a Therapeutic ↑ (135%)
Carbamazepine19,31 Fixed dose n/a Therapeutic19 ↔ 19
Valproic acid19 Fixed dose n/a Therapeutic ↔
Antipyrine26 Fixed dose n/a Not available Not available
Midazolam32 Fixed dose n/a Not available Not available
Caffeine37 Fixed dose n/a Not available Not available
TBM, total body measurement; ABM, adjusted body measurement; ↑, increased in comparison to controls; ↓, decreased in comparison to controls; 
↔, equal to controls; (%), % of controls.
a
Comparison of exposure between obese and control subjects based on clinical outcomes (overall survival, event-free survival, and cumulative 
incidence of relapse).33
b
Test dose used for PK comparison.21
c
Acetaminophen single-dose regimen: 5 mg/kg, maximum 325 mg, the mean dose administered was 3.6 mg/kg (SD 0.8).25
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Table 3
Observed PK Changes in Obese Children
Drug Volume of distributiona Clearancea
Analgesics/anesthetics
 Acetaminophen25 ↓ (83%) ↔
 Antipyrine26 ↓ (76%) ↓ (50%)
Antibiotics
 Cefazolin28 ↔ ↔
 Gentamicin29 ↓ (71%) b
 Tobramycin28 ↓ (75%) b ↔
 Vancomycin17 ↓ (81%) ↓ (80%)
Anticonvulsants
 Carbamazepine31 ↓ (89%) ↓ (63%)
 Midazolam32 ↔
Antineoplastics
 Busulfan21 ↓ (84%) b
 Cytarabine33 ↔
 Doxorubicin34,35 ↑ (113%) ↔
 Etoposide35 ↔




 Caffeine37 ↓ (65%) ↓ (30%)
 Theophylline23 ↓ (69%) b
V and CL are expressed as a percentage of mean values in non-obese controls. ↑, increased in comparison to controls; ↓, decreased in comparison 
to controls; ↔, equal to control.
a
PK parameters are weight-normalized (e.g., volume of distribution in L/kg). If authors did not report weight-normalized values (antipyrine, 
carbamazepine, caffeine, and mercaptopurine), then weight-normalized parameters were calculated by dividing reported values by individual or 
study mean weight values.
b
Significant difference found in cited study.
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